Compounds > cgc 11093

Page last updated: 2024-11-12

cgc 11093

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

CGC 11093: may prove useful in promoting regression of choroidal neovascularization [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	10026462
MeSH ID	M0504976

Synonyms (14)

Synonym
cgc-11093
cgc-11098
cgc 11093
1,2-cyclopropanedimethanamine, n,n'-bis(4-(ethylamino)butyl)-, tetrahydrochloride, (1r,2s)-rel-
306292-65-9
cgc 11098
unii-mx8724vfp3
3,8,13,18-tetraaza-10,11-((e)-1,2-cyclopropyl)eicosane tetrahydrochloride
mx8724vfp3 ,
306292-64-8
1,2-cyclopropanedimethanamine, n,n'-bis(4-(ethylamino)butyl)-, tetrahydrochloride, (1r,2r)-rel-
n-ethyl-n'-[[2-[[4-(ethylamino)butylamino]methyl]cyclopropyl]methyl]butane-1,4-diamine;tetrahydrochloride
n~1~,n~1'~-[cyclopropane-1,2-diylbis(methylene)]bis(n~4~-ethylbutane-1,4-diamine)--hydrogen chloride (1/4)
DTXSID40952897

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
putrescine [no description available]	2.02	1	0	alkane-alpha,omega-diamine	antioxidant; fundamental metabolite
spermine [no description available]	2.03	1	0	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	2.04	1	0	diazine; pyrazines	Daphnia magna metabolite
bortezomib [no description available]	2.04	1	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
cgc 11047 CGC 11047: may prove useful in promoting regression of choroidal neovascularization	2.03	1	0
s-adenosylmethionine (R)-S-adenosyl-L-methionine : An S-adenosyl-L-methionine that has R-configuration.. S-adenosyl-L-methionine zwitterion : A zwitterionic tautomer of S-adenosyl-L-methionine arising from shift of the proton from the carboxy group to the amino group.. (R)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has R-configuration; major species at pH 7.3.. (S)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has S-configuration; major species at pH 7.3.. S-adenosyl-L-methionine : A sulfonium compound that is the S-adenosyl derivative of L-methionine. It is an intermediate in the metabolic pathway of methionine.	2.01	1	0	organic cation; sulfonium compound	coenzyme; cofactor; human metabolite; micronutrient; Mycoplasma genitalium metabolite; nutraceutical; Saccharomyces cerevisiae metabolite

Condition	Indicated	Relationship Strength	Studies	Trials
Cancer of Lung [description not available]	0	2.04	1	0
Kahler Disease [description not available]	0	2.04	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	2.04	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	0	2.04	1	0
Choroid Neovascularization [description not available]	0	2.03	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.03	1	0
Rupture Forcible or traumatic tear or break of an organ or other soft part of the body.	0	2.03	1	0
Neovascularization, Optic Disc [description not available]	0	2.03	1	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	0	2.03	1	0
Retinal Neovascularization Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.	0	2.03	1	0
Adenocarcinoma, Basal Cell [description not available]	0	2.03	1	0
Cancer of Colon [description not available]	0	2.03	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	2.03	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	0	2.03	1	0
Cancer of Prostate [description not available]	0	2.01	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	2.01	1	0
Breast Cancer [description not available]	0	2.03	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2.03	1	0